Most recent


APL in the obese: Should we treat it differently?

Jitani AK, et al. APL 2017:PO031 Background Differentiation syndrome (DS) is a life-threatening complication in acute promyelocytic leukemia (APL). Studies have reported that a high body mass index (BMI) is the most powerful predictor of DS, with an odds ratio of...

Front-line therapy of APL: Randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines — a prospective, multicentre, randomized clinical trial of the German Acute Myeloid Leukemia Cooperative Group

Lengfelder E, et al. APL 2017:CO027 Background The APL-2005 study was started as an Acute Myeloid Leukemia Cooperative Group (AMLCG) trial with the intention to be part of an acute promyelocytic leukemia (APL) intergroup study with the PETHEMA LPA99 protocol as a...

ATO and ATRA for the treatment of childhood APL

Gurnari C, et al. APL 2017:PO041 Background Acute promyelocytic leukemia (APL) accounts for about 5%–10% of all cases of childhood acute myeloid leukemia, with the disease being significantly more frequent in children of Mediterranean origin.1 Recent studies with...

Prolonged ATO and ATRA therapy for relapsed APL

Cicconi L, et al. APL 2017:CO032 Background Arsenic trioxide (ATO) combined with all-trans retinoic acid (ATRA) is the standard salvage regimen for relapsed acute promyelocytic leukemia (APL); however, the optimal consolidation strategy remains undefined. The approach...

APL in patients aged >70 years: Real-life results

De Luca ML, et al. APL 2017:PO038 Background In the treatment of very elderly patients with acute promyelocytic leukemia (APL), very few cases have been described in a real-life setting. Therefore, at the 7th International Symposium on APL, De Luca and colleagues...

Twitter feed

Video: Dr. Mark Vincent Discusses Outcomes in Pancreatic Adenocarcinoma Patients with Genetic Alterations in DNA Da… https://t.co/35E7MSeX3V
h J R
RT @medoncdoc: CO26. first evidence of survival benefit in MSS patients using immunotherapy. 6.6 mo vs 4.1 mo.#GI19 @CDNCancerTrials great…
h J R
RT @tehfem: Adjuvant HIPEC in CRC at high risk for peritoneal mets No benefit #GI19 https://t.co/tYIw9B3eme
h J R
RT @GillSharlene: How long to optimally wait for resection after neoadjuvant therapy for early stage rectal cancer? Looks like the answer…
h J R
Video: Dr. Winson Cheung on Prognostic Factors Associated with Long-Term Survival in Chemotherapy-Treated Advanced… https://t.co/yBP1srRQkb
h J R